These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19409694)

  • 1. Editorial comment on: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
    Volpe A
    Eur Urol; 2009 Oct; 56(4):735-6. PubMed ID: 19409694
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
    Porst H; McVary KT; Montorsi F; Sutherland P; Elion-Mboussa A; Wolka AM; Viktrup L
    Eur Urol; 2009 Oct; 56(4):727-35. PubMed ID: 19409693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
    J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
    Kloner RA; Jackson G; Hutter AM; Mittleman MA; Chan M; Warner MR; Costigan TM; Vail GM
    Am J Cardiol; 2006 Jun; 97(12):1778-84. PubMed ID: 16765134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction.
    Hatzichristou D; Gambla M; Rubio-Aurioles E; Buvat J; Brock GB; Spera G; Rose L; Lording D; Liang S
    Diabet Med; 2008 Feb; 25(2):138-46. PubMed ID: 18290855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of tadalafil on erectile dysfunction: on-demand versus once-daily dosing].
    Tang YX; Zhou HB; Peng SL; Jiang XZ; He LY; Li DJ
    Zhonghua Nan Ke Xue; 2012 May; 18(5):472-4. PubMed ID: 22741449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of erectile dysfunction of neurogenic genesis with inhibitors of phosphodiesterase of type 5 in patients with diabetes mellitus].
    Kurbatov DG; Rozhivanov RV
    Urologiia; 2009; (5):48-9. PubMed ID: 20209871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial.
    Seftel A; Goldfischer E; Kim ED; Dula E; Zeigler H; Burns P
    J Urol; 2011 Jan; 185(1):243-8. PubMed ID: 21074803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US.
    Rajfer J; Aliotta PJ; Steidle CP; Fitch WP; Zhao Y; Yu A
    Int J Impot Res; 2007; 19(1):95-103. PubMed ID: 16871272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men.
    Guo YL; Zhu JC; Pan TM; Ding Q; Wang YX; Cheong NF; Lim E; Shen W; Venugopalan M; Chan M
    Int J Urol; 2006 Jun; 13(6):721-7. PubMed ID: 16834650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Porst H; Giuliano F; Glina S; Ralph D; Casabé AR; Elion-Mboussa A; Shen W; Whitaker JS
    Eur Urol; 2006 Aug; 50(2):351-9. PubMed ID: 16766116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment.
    de la Rosette JJ
    Urology; 2010 Jun; 75(6):1458. PubMed ID: 20513508
    [No Abstract]   [Full Text] [Related]  

  • 14. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction.
    Saylan M; Khalaf I; Kadioglu A; Shoair KZ; Beheiry A; Wang WC; Kopernicky V; Esen A
    Int J Clin Pract; 2006 Jul; 60(7):812-9. PubMed ID: 16846400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment on: comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.
    Salonia A
    Eur Urol; 2008 Jul; 54(1):211-2. PubMed ID: 18395330
    [No Abstract]   [Full Text] [Related]  

  • 17. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.
    Donatucci CF; Brock GB; Goldfischer ER; Pommerville PJ; Elion-Mboussa A; Kissel JD; Viktrup L
    BJU Int; 2011 Apr; 107(7):1110-6. PubMed ID: 21244606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels.
    Proietti M; Aversa A; Letizia C; Rossi C; Menghi G; Bruzziches R; Merla A; Spera G; Salsano F
    J Rheumatol; 2007 Aug; 34(8):1712-7. PubMed ID: 17611982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Should we prescribe phosphodiesterase inhibitors for the treatment of symptomatic benign prostatic hyperplasia].
    Caviezel A; Iselin CE
    Rev Med Suisse; 2011 Dec; 7(320):2394-7. PubMed ID: 22232868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Zhao C; Kim SH; Lee SW; Jeon JH; Kang KK; Choi SB; Park JK
    BJU Int; 2011 Jun; 107(12):1943-7. PubMed ID: 21054754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.